241 results on '"Wang, Liang-Chuan"'
Search Results
52. Treating Tumors With a Vaccinia Virus Expressing IFNβ Illustrates the Complex Relationships Between Oncolytic Ability and Immunogenicity
53. Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation
54. Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
55. HDAC5 controls the functions of Foxp3+ T-regulatory and CD8+ T cells
56. Labeling of Oxidizable Proteins with a Photoactivatable Analog of the Antitumor Agent DMXAA: Evidence for Redox Signaling in Its Mode of Action
57. Activation of the Nucleotide Oligomerization Domain Signaling Pathway by the Non-bacterially Derived Xanthone Drug 5′6-Dimethylxanthenone-4-acetic Acid (Vadimezan)
58. Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)
59. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors
60. Inhibition of p300 impairs [Foxp3.sup.+] T regulatory cell function and promotes antitumor immunity
61. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor
62. Mesothelin, a novel immunotherapy target for triple negative breast cancer
63. Pharmacologic Activation of the Innate Immune System to Prevent Respiratory Viral Infections
64. Monocyte Chemoattractant Protein-1 Blockade Inhibits Lung Cancer Tumor Growth by Altering Macrophage Phenotype and Activating CD8+ Cells
65. 820 MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells
66. 814 MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity
67. Induction of tumour necrosis factor and interferon-γ in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites
68. Abstract 4480: Preclinical characterization of potent and selective oral PD-L1 small-molecule antagonists
69. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines
70. Abstract 2618: Agonist antibodies targeting OX40 and GITR enhance the activity of the IDO1-selective inhibitor epacadostat in preclinical models
71. Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitroand In Vivo
72. Abstract 2294: Reversible regulation of chimeric antigen receptor surface expression
73. Abstract 4904: The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models
74. Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells
75. HDAC5 controls the functions of Foxp3+T-regulatory and CD8+T cells
76. Abstract C103: The combination of PI3kδ-selective inhibition and immunomodulation shows efficacy in solid tumor models
77. Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents
78. Abstract B78: Histamine dihydrochloride in the treatment of mesothelioma
79. Abstract B22: A chimeric antigen receptor (CARs) based upon a killer immunoglobulin-like receptor (KIR) triggers robust cytotoxic activity in solid tumors
80. Abstract B12: Inhibition of the transcription factor Ikaros augments the tumoricidal capacity of CD8+ T cells expressing chimeric antigen receptor
81. Abstract 4293: Histamine dihydrochloride as an immune modulator for solid tumors
82. Abstract 1336: Novel immunotherapeutic activity of JAK and PI3Kδ inhibitors in a model of pancreatic cancer
83. Abstract 3187: Depleting cells expressing fibroblast activation protein disrupts tumor-promoting desmoplasia
84. Abstract 3142: Inhibition of the transcription factor Ikaros augments the tumoricidal capacity of CD8+ T cells expressing chimeric antigen receptors
85. CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis
86. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
87. Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
88. 21. Non-CD3-Based Chimeric Antigen Receptor (CARs) with Enhanced Anti-Tumor Activity in Solid Tumors
89. Neutrophil Influx and Chemokine Production during the Early Phases of the Antitumor Response to the Vascular Disrupting Agent DMXAA (ASA404)1
90. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
91. Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors
92. Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
93. Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
94. Neutrophils inhibit tumor growth at early stages of tumor formation. (P2006)
95. HDAC5 controls the functions of Foxp3+ T-regulatory and CD8+ T cells.
96. The receptor for advanced glycation end products mediates lung endothelial activation by RBCs
97. Abstract A3: Enhanced effector responses in CAR-redirected CD8+ T cells deficient in diacylglycerol kinases.
98. Abstract PR14: Fibroblast activation protein as a universal target for chimeric antigen receptor T cell therapy in solid tumors.
99. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery
100. A Preclinical Model Tto Study Tumor-Infiltrating Lymphocyte (TIL) Anergy/Exhaustion In Adoptive T Cell Therapy (ACT) Of Thoracic Malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.